These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10093483)

  • 1. [Understanding and treating levodopa-induced dyskinesias].
    Hadj Tahar A; Bédard PJ
    Tunis Med; 1998 Dec; 76(12):437-47. PubMed ID: 10093483
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
    Cenci MA
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S263-7. PubMed ID: 18267248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.
    Frucht S; Fahn S; Chin S; Dhawan V; Eidelberg D
    Mov Disord; 2000 Mar; 15(2):340-3. PubMed ID: 10752591
    [No Abstract]   [Full Text] [Related]  

  • 7. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 9. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.
    Alves R; Barbosa E; Scaff M
    Mov Disord; 2006 Dec; 21(12):2267-8; author reply 2268. PubMed ID: 17078068
    [No Abstract]   [Full Text] [Related]  

  • 11. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 12. Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies.
    Widner H; Defer GL
    Mov Disord; 1999; 14 Suppl 1():60-6. PubMed ID: 10493405
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
    Picconi B; Calabresi P
    Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
    Deogaonkar M; Subramanian T
    Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
    Cenci MA; Ohlin KE; Rylander D
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S59-63. PubMed ID: 20083009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 18. Surgical approach to l-dopa-induced dyskinesias.
    Sankar T; Lozano AM
    Int Rev Neurobiol; 2011; 98():151-71. PubMed ID: 21907086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term complications of treatment with levodopa].
    Castro García A; Sesar Ignacio A
    Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685
    [No Abstract]   [Full Text] [Related]  

  • 20. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.